Approval of esketamine for treatment-resistant depression.

Singh, Jaskaran B; Daly, Ella J; Mathews, Maju; Fedgchin, Maggie; Popova, Vanina; Hough, David; Drevets, Wayne C

Singh, Jaskaran B; Daly, Ella J; Mathews, Maju; Fedgchin, Maggie; Popova, Vanina; Hough, David; Drevets, Wayne C.

Afiliação

Singh JB; Neuroscience Clinical Development, Janssen Research & Development, San Diego, CA, USA.
Daly EJ; Janssen Scientific Affairs, Titusville, NJ 08560, USA. Electronic address: edaly2@its.jnj.com.
Mathews M; Neuroscience Global Medical Affairs, Janssen Research & Development, Titusville, NJ, USA.
Fedgchin M; Neuroscience Clinical Development, Janssen Research & Development, Titusville, NJ, USA.
Popova V; Neuroscience Clinical Development, Janssen Research & Development, Beerse, Belgium.
Hough D; Neuroscience Global Medical Affairs, Janssen Research & Development, Titusville, NJ, USA.
Drevets WC; Neuroscience Clinical Development, Janssen Research & Development, San Diego, CA, USA.

Lancet Psychiatry ; 7(3): 232-235, 2020 03.

Article em En | MEDLINE | ID: mdl-32087801

Assuntos

Depressão; Transtorno Depressivo Resistente a Tratamento; Combinação de Medicamentos; Humanos; Ketamina; Pregnanolona; Estados Unidos; United States Food and Drug Administration; beta-Ciclodextrinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Depressão / Transtorno Depressivo Resistente a Tratamento Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google